SPARC and cancer: Other authors extended the research from developing markers to predict the outcome of OPSCC patients (e.g., CD8+ TIL counts, age, T-stage, and E2 expression) [56] by analyzing different gene expression (e.g., SPARC, psoriasin, type I collagen and galectin-1) between HPV-positive and HPV-negative TSCC (tonsillar squamous cell carcinoma) and BOTSCC (base of tongue squamous cell carcinoma) [57] or analyzing other cancers such as HPV-related uvula, soft palate, and hypopharyngeal cancers [58,59].